\
&
Contact us
Research Infrastructures Health Culture and society Security
During the past months, the Commission has published updated versions of several key documents for application to the call topics of the main Horizon Europe Work Programme (WP) 2025: Standard application form for applicants - last updated on 16 December 2024 Horizon Europe Programme Guide - last updated on 15 May 2025 General Annexes to... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.